puerarin | 100272-46-6

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 异黄酮类化合物
• 英文名称: puerarin
• 英文别名: 7-hydroxy-3-(4-hydroxyphenyl)-8-[(3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one
• CAS: 100272-46-6
• 化学式: C₂₁H₂₀O₁₀
• 分子量: 432.384
• InChiKey: RIQBSCOBOICSFR-WGLXEVCESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  31
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  166
• 氢给体数：
  6
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  daidzein 8-C-apiosyl(1-6) glucoside 在 盐酸 作用下， 以 甲醇 为溶剂， 反应 2.0h， 以30 mg的产率得到puerarin
  参考文献：
  名称：

  Kinjo, Jun-Ei; Furusawa, Jun-Ichi; Baba, Junko, Chemical and pharmaceutical bulletin, 1987, vol. 35, # 12, p. 4846 - 4850

  摘要：

  DOI：

文献信息

• SUBSTANCES CAPABLE OF POTENTIATING LAMININ 5 PRODUCTIVITY IN EPIDERMAL CELLS AND UTILIZATION THEREOF
  申请人：SHISEIDO COMPANY LIMITED

  公开号：EP1426030A1

  公开（公告）日：2004-06-09

  The invention provides cosmetics or dermatological compositions comprising plant extract or whey extract having an action to potentiate laminin 5 productivity in the epidermal cells. They have mainly the action and efficacy to prevent or improve aging in the skin.

  本发明提供了由植物提取物或乳清提取物组成的化妆品或皮肤科组合物，它们具有促进表皮细胞中层粘蛋白 5 生产力的作用。它们主要具有防止或改善皮肤老化的作用和功效。
• Substances capable of potentiating laminin 5 productivity in epidermal cells and their use
  申请人：SHISEIDO COMPANY, LTD.

  公开号：EP2113245A2

  公开（公告）日：2009-11-04

  The invention provides cosmetics or dermatological compositions comprising plant extract or whey extract having an action to potentiate laminin 5 productivity in the epidermal cells. They have mainly the action and efficacy to prevent or improve aging in the skin.

  本发明提供了由植物提取物或乳清提取物组成的化妆品或皮肤科组合物，它们具有促进表皮细胞中层粘蛋白 5 生产力的作用。它们主要具有防止或改善皮肤老化的作用和功效。
• Edible composition
  申请人：Conopco, Inc.

  公开号：US10806744B2

  公开（公告）日：2020-10-20

  Foods or meals high in available carbohydrate such as sucrose or starch increase postprandial blood glucose concentrations. According to Node et al. (Cardiovascular diabetology, 8, 23 (2009)), repeated high post-prandial plasma glucose “spikes” are associated with an increased risk of developing type II diabetes. Unregulated glycemic excursions are undesirable, and any reduction or “blunting” of the post-prandial glucose concentration in blood is potentially beneficial. This invention relates to an edible composition for delay of intestinal glucose uptake through synergistic inhibition of both active sodium glucose co-transporter 1 (SGLT1) and passive glucose transporter 2 (GLUT2) leading to flattening or blunting of the post-prandial glucose peak. Thus in a first aspect of the invention, an edible composition provided in the form of a single serving of one or more unit dosages comprising a combination of 2 to 200 mg of at least one homoisoflavonoid and 20 to 2000 mg of at least one flavonoid monoglucoside, and salts thereof.

  蔗糖或淀粉等碳水化合物含量高的食物或膳食会增加餐后血糖浓度。根据 Node 等人（《心血管糖尿病学》，8, 23 (2009)）的研究，反复出现餐后血浆葡萄糖 "飙升 "与罹患 II 型糖尿病的风险增加有关。不受调节的血糖偏移是不可取的，任何降低或 "钝化 "餐后血糖浓度的做法都可能是有益的。本发明涉及一种可食用组合物，通过协同抑制活性钠葡萄糖协同转运体 1（SGLT1）和被动葡萄糖转运体 2（GLUT2），延缓肠道葡萄糖摄取，从而使餐后葡萄糖峰值变平或变钝。因此，在本发明的第一方面，一种以一份或多份单位剂量形式提供的可食用组合物，包含 2 至 200 毫克至少一种同异黄酮和 20 至 2000 毫克至少一种黄酮单葡糖苷及其盐的组合。
• Glycosylation modification of bioactive compounds and drugs by plant glycosyltransferases (UGTs)
  申请人：UNIVERSITY OF NORTH TEXAS

  公开号：US11261477B2

  公开（公告）日：2022-03-01

  In alternative embodiments, provided are methods for the glycosylation modification of bioactive compounds and drugs using isolated, recombinant or genetically modified uridine diphosphate glycosyl-transferases (UGTs). In alternative embodiments, provided are methods for modifying UGTs to generate recombinant UGTs with altered donor and/or acceptor specificities. In alternative embodiments, provided are methods for screening for recombinantly engineered UGTs with new or altered properties, for example, for new or altered donor and/or acceptor specificities, where in alternative embodiments the screening comprise use of bacterial, yeast or baculovirus expression system.

  在另一个实施方案中，提供了使用分离的、重组的或遗传修饰的二磷酸尿苷糖基转移酶（UGTs）对生物活性化合物和药物进行糖基化修饰的方法。在另一些实施方案中，提供了对 UGTs 进行修饰以产生具有改变的供体和/或受体特异性的重组 UGTs 的方法。在另一个实施方案中，提供了筛选具有新的或改变的特性的重组工程UGT的方法，例如，筛选新的或改变的供体和/或受体特异性的方法，其中在另一个实施方案中，筛选包括使用细菌、酵母或杆状病毒表达系统。
• Substance capable of potentiating laminin 5 productivity in epidermal cells and utilization thereof
  申请人：——

  公开号：US20040202638A1

  公开（公告）日：2004-10-14

  The invention provides cosmetics or dermatological compositions comprising plant extract or whey extract having an action to potentiate laminin 5 productivity in the epidermal cells. They have mainly the action and efficacy to prevent or improve aging in the skin.

  本发明提供了由植物提取物或乳清提取物组成的化妆品或皮肤科组合物，它们具有促进表皮细胞中层粘蛋白 5 生产力的作用。它们主要具有防止或改善皮肤老化的作用和功效。